Guillain-Barré syndrome following COVID-19 vaccine: A case report

Area of Science:

• Neurology
• Immunology
• Vaccinology

Background:

• Coronavirus disease (COVID-19) is a significant global health concern.
• Vaccination is a primary strategy for controlling the COVID-19 pandemic.
• COVID-19 vaccines have demonstrated efficacy but potential adverse effects require ongoing investigation.

Observation:

• This report focuses on a specific case following vaccination with the Sinopharm COVID-19 vaccine.
• The patient developed symptoms indicative of Guillain-Barré Syndrome (GBS).

Findings:

• A direct association between the Sinopharm COVID-19 vaccine and the subsequent development of Guillain-Barré Syndrome is presented.
• This case highlights a rare neurological adverse event potentially linked to COVID-19 vaccination.

Implications:

• Understanding rare vaccine-associated adverse events is crucial for vaccine safety monitoring.
• This case contributes to the broader understanding of the neurological complications associated with COVID-19 vaccines.
• Further research may be needed to elucidate the mechanisms linking specific vaccines to GBS.